Identification
NamePropofol
Accession NumberDB00818  (APRD01201, EXPT02558, DB05893)
TypeSmall Molecule
GroupsApproved, Investigational, Vet Approved
Description

Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associated with less frequent side effects (e.g. drowsiness, nausea, vomiting) than with thiopental, methohexital, and etomidate. Propofol may be used prior to diagnostic procedures requiring anaesthesia, in the management of refractory status epilepticus, and for induction and/or maintenance of anaesthesia prior to and during surgeries.

Structure
Thumb
Synonyms
2,6-Bis(1-methylethyl)phenol
2,6-Diisopropylphenol
Disoprivan
Disoprofol
Propofol
Propofolum
External IDs ICI 35-868 / ICI 35,868 / ICI 35868 / ICI-35868 / ICI35,868
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act PropofolEmulsion10 mgIntravenousActavis Pharma Company2015-11-20Not applicableCanada
DiprivanInjection, emulsion10 mg/mLIntravenousFresenius Kabi2009-11-13Not applicableUs
DiprivanInjection, emulsion10 mg/mLIntravenousGeneral Injectables & Vaccines2010-03-01Not applicableUs
Diprivan 1%Emulsion1 %IntravenousAstra Zeneca1993-12-31Not applicableCanada
PMS-propofolEmulsion10 mgIntravenousPharmascience Inc2002-03-01Not applicableCanada
PropofolInjection, emulsion10 mg/mLIntravenousAPP Pharmaceuticals, Inc.2009-10-07Not applicableUs
Propofol InjectionEmulsion10 mgIntravenousHospira, Inc.2004-04-022011-11-28Canada
Propofol InjectionEmulsion10 mgIntravenousFresenius Kabi2015-06-01Not applicableCanada
Propofol InjectionEmulsion10 mgIntravenousHospira, Inc.1998-02-05Not applicableCanada
Propofol InjectionEmulsion10 mgIntravenousNovopharm Limited2000-07-052013-04-01Canada
Propofol-II InjectionEmulsion10 mgIntravenousHospira, Inc.2013-06-11Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PropofolInjection, emulsion10 mg/mLIntravenousActavis Pharma Company2015-10-30Not applicableUs
PropofolInjection, emulsion10 mg/mLIntravenousTeva Parenteral Medicines, Inc.2007-06-212017-02-01Us
PropofolInjection, emulsion10 mg/mLIntravenousGeneral Injectables & Vaccines2014-08-21Not applicableUs
PropofolInjection, emulsion10 mg/mLIntravenousTeva Parenteral Medicines, Inc.2007-06-212017-02-01Us
PropofolInjection, emulsion10 mg/mLIntravenousHospira, Inc.2006-03-17Not applicableUs
PropofolInjection, emulsion10 mg/mLIntravenousTeva Parenteral Medicines, Inc.2007-06-212017-02-01Us
PropofolInjection, emulsion10 mg/mLIntravenousSagent Pharmaceuticals2014-07-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnepolHa Na Pharm
AnesproBehrens
AnesvanChi Sheng
CritifolAbbott
DiprivanNot Available
DisoprivanAstraZeneca
DormofolActavis
FresofolBoryung
GobbifolGobbi
HipnolamAC Farma
HyproCelon
IV-ProClaris Lifesciences
LipuroB. Braun Medical
Oleo-LaxFada
PlofedWarsaw Pharmaceutical Works
ProfolBiogalenic
ProfolenBlausiegel
PropofabbHospira
PropofilAlvia
PropogenGenepharm
PropolipidFresenius
PropovanBharat Serums
PropovenFresenius
ProviveAFT
RapinovetNot Available
RecofolBayer
SafolNovell
TrivamHana Pharm
TroypofolTroikaa
UnifolClaris Lifesciences
Brand mixturesNot Available
Categories
UNIIYI7VU623SF
CAS number2078-54-8
WeightAverage: 178.2707
Monoisotopic: 178.135765198
Chemical FormulaC12H18O
InChI KeyOLBCVFGFOZPWHH-UHFFFAOYSA-N
InChI
InChI=1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3
IUPAC Name
2,6-bis(propan-2-yl)phenol
SMILES
CC(C)C1=CC=CC(C(C)C)=C1O
Pharmacology
Indication

Used for induction and/or maintenance of anaesthesia and for management of refractory status epilepticus.

Structured Indications Not Available
Pharmacodynamics

Propofol is a sedative-hypnotic agent for use in the induction and maintenance of anesthesia or sedation. Intravenous injection of a therapeutic dose of propofol produces hypnosis rapidly with minimal excitation, usually within 40 seconds from the start of an injection (the time for one arm-brain circulation).

Mechanism of action

The action of propofol involves a positive modulation of the inhibitory function of the neurotransmitter gama-aminobutyric acid (GABA) through GABA-A receptors.

TargetKindPharmacological actionActionsOrganismUniProt ID
Gamma-aminobutyric acid receptor subunit beta-2Proteinyes
potentiator
HumanP47870 details
Gamma-aminobutyric acid receptor subunit beta-3Proteinyes
potentiator
HumanP28472 details
Sodium channel protein type 4 subunit alphaProteinunknown
inhibitor
HumanP35499 details
Sodium channel protein type 2 subunit alphaProteinunknown
inhibitor
HumanQ99250 details
GABA-A receptor (anion channel)Protein groupyes
positive allosteric modulator
Humannot applicabledetails
Related Articles
Absorption

Rapid - time to onset of unconsciousness is 15-30 seconds, due to rapid distribution from plasma to the CNS. Distribution is so rapid that peak plasma concentrations cannot be readily measured. Duration of action is 5-10 minutes.

Volume of distribution
  • 60 L/kg [healthy adults]
Protein binding

95 to 99%, primarily to serum albumin and hemoglobin

Metabolism

Hepatically metabolized mainly by glucuronidation at the C1-hydroxyl. Hydroxylation of the benzene ring to 4-hydroxypropofol may also occur via CYP2B6 and 2C9 with subsequent conjugation to sulfuric and/or glucuronic acid. Hydroxypropofol has approximately 1/3 of hypnotic activity of propofol.

SubstrateEnzymesProduct
Propofol
4-HydroxypropofolDetails
Propofol
Propofol glucuronideDetails
Propofol glucuronide
Not Available
1-Quinol glucuronideDetails
4-Hydroxypropofol
1-Quinol glucuronideDetails
4-Hydroxypropofol
Not Available
4-Quinol sulfateDetails
Route of elimination

It is chiefly eliminated by hepatic conjugation to inactive metabolites which are excreted by the kidney.

Half life

Initial distribution phase t1/2α=1.8-9.5 minutes. Second redistirubtion phase t1/2β=21-70 minutes. Terminal elimination phase t1/2γ=1.5-31 hours.

Clearance
  • 23 - 50 mL/kg/min
  • 1.6 - 3.4 L/min [70 Kg adults]
Toxicity

Overdosage may increase pharmacologic and adverse effects or cause death.

IV LD50=53 mg/kg (mice), 42 mg/kg (rats). Oral LD50 (as a solution in soybean oil)=1230 mg/kg (mice), 600 mg/kg (rats)

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Propofol is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Propofol can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Propofol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Propofol is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Propofol is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Propofol is combined with Acetazolamide.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Propofol is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Propofol is combined with Agomelatine.Approved, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Propofol.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Propofol is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Propofol.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Propofol.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Propofol is combined with Sage 547.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Propofol is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Propofol.Approved, Illicit, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Propofol.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Propofol.Approved
AmiodaroneThe metabolism of Propofol can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Propofol is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Propofol is combined with Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Propofol.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Propofol is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Propofol is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Propofol is combined with Amperozide.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Propofol.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Propofol.Approved
AnagrelidePropofol may increase the QTc-prolonging activities of Anagrelide.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Propofol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Propofol.Approved
AprepitantThe serum concentration of Propofol can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Propofol.Approved, Investigational
ArmodafinilThe metabolism of Propofol can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Propofol.Approved
Arsenic trioxidePropofol may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherPropofol may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Propofol is combined with Articaine.Approved
AsenapinePropofol may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe metabolism of Propofol can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Propofol.Approved
AtomoxetineThe metabolism of Propofol can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Propofol is combined with Azaperone.Vet Approved
AzelastinePropofol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Propofol is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Propofol.Approved
AzithromycinPropofol may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Propofol is combined with Baclofen.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Propofol.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Propofol is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Propofol.Approved
BedaquilinePropofol may increase the QTc-prolonging activities of Bedaquiline.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Propofol.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Propofol.Approved
BenperidolThe risk or severity of adverse effects can be increased when Propofol is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Propofol is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Propofol is combined with Benzyl alcohol.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Propofol.Approved, Withdrawn
BetaxololThe metabolism of Propofol can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Propofol can be decreased when it is combined with Bexarotene.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Propofol.Approved
BoceprevirThe metabolism of Propofol can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Propofol can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Propofol can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Propofol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Propofol is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Propofol is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved
BromazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Bromazepam.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Propofol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Propofol is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Propofol is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Propofol.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Propofol.Approved, Investigational
BuprenorphinePropofol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Propofol can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Propofol.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Propofol.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Propofol is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Propofol is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Propofol is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Propofol is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Propofol.Approved, Illicit, Vet Approved
CaffeineThe metabolism of Propofol can be decreased when combined with Caffeine.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Propofol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Propofol.Approved
CapecitabineThe metabolism of Propofol can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Propofol.Approved
CarbamazepineThe metabolism of Propofol can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Propofol.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Propofol is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Propofol is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Propofol is combined with Carisoprodol.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Propofol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Propofol.Approved, Investigational
CelecoxibThe metabolism of Propofol can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Propofol can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Propofol is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Propofol is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Propofol can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Propofol.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Propofol is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Propofol is combined with Chloroprocaine.Approved
ChloroquinePropofol may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Propofol.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Propofol is combined with Chlorphenamine.Approved
ChlorpromazinePropofol may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Propofol is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Propofol.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Propofol is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Propofol can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Propofol.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Propofol.Approved
CimetidineThe metabolism of Propofol can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Propofol can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Propofol.Approved, Vet Approved
CiprofloxacinPropofol may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisapridePropofol may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramPropofol may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinThe metabolism of Propofol can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Propofol can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Propofol.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Propofol is combined with Clidinium.Approved
ClobazamThe metabolism of Propofol can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Propofol.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Propofol is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Propofol can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Propofol is combined with Clonidine.Approved
ClopidogrelThe metabolism of Propofol can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Propofol.Approved, Illicit
ClotrimazoleThe metabolism of Propofol can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapinePropofol may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe serum concentration of Propofol can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Propofol can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Propofol.Approved, Illicit
ConivaptanThe serum concentration of Propofol can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibPropofol may increase the QTc-prolonging activities of Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Propofol is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Propofol is combined with Cyclobenzaprine.Approved
CyclosporineThe metabolism of Propofol can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Propofol is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Propofol can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Propofol can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Propofol is combined with Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Propofol.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Propofol.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Propofol is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Propofol can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Propofol can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Propofol can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Propofol can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Propofol can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Propofol is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Propofol is combined with Desflurane.Approved
DesipramineThe metabolism of Propofol can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Propofol is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Propofol is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Propofol is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Propofol can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Propofol is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Propofol.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Propofol is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Propofol.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Propofol is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Diazepam.Approved, Illicit, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Propofol.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Propofol is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Propofol is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Propofol can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Propofol is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Propofol is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Propofol can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Propofol is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Propofol.Approved
DiphenhydramineThe metabolism of Propofol can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Propofol is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Propofol.Approved
DisopyramidePropofol may increase the QTc-prolonging activities of Disopyramide.Approved
DisulfiramThe metabolism of Propofol can be decreased when combined with Disulfiram.Approved
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Propofol.Approved
DolasetronPropofol may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidonePropofol may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Propofol is combined with Doramectin.Vet Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Propofol.Approved
DoxepinThe risk or severity of adverse effects can be increased when Propofol is combined with Doxepin.Approved
DoxorubicinThe metabolism of Propofol can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Propofol can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Propofol is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved, Illicit
DronedaronePropofol may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Propofol is combined with Drotebanol.Experimental, Illicit
DuloxetinePropofol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Propofol.Approved
EcgonineThe risk or severity of adverse effects can be increased when Propofol is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Propofol is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Propofol can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Propofol.Approved
EliglustatPropofol may increase the QTc-prolonging activities of Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Propofol is combined with Pregnanolone.Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Propofol.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Propofol.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Propofol.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Propofol.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Propofol is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Propofol can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Propofol.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Propofol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Propofol.Approved
ErythromycinPropofol may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramPropofol may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Propofol can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Propofol.Approved
EsomeprazoleThe metabolism of Propofol can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Propofol is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Propofol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Propofol.Approved
EthanolPropofol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Propofol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Propofol is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Propofol is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Propofol is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Propofol is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Propofol is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Propofol is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Propofol is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Propofol is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Propofol.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Propofol is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Propofol is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Propofol can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Propofol is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Propofol is combined with Felbamate.Approved
FelodipineThe metabolism of Propofol can be decreased when combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Propofol is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Propofol.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Propofol.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Propofol.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Propofol is combined with Fexofenadine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Propofol.Approved
FlecainidePropofol may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Propofol.Approved
FloxuridineThe metabolism of Propofol can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Propofol can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Propofol is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Flunitrazepam.Approved, Illicit
FluorouracilThe metabolism of Propofol can be decreased when combined with Fluorouracil.Approved
FluoxetinePropofol may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolPropofol may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Propofol.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Propofol.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Propofol is combined with Fluspirilene.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Propofol is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Propofol can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Propofol can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Propofol can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Propofol can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Propofol.Approved
FosphenytoinThe metabolism of Propofol can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Fospropofol.Approved, Illicit
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Propofol.Approved, Vet Approved
Fusidic AcidThe serum concentration of Propofol can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Propofol is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Propofol is combined with gabapentin enacarbil.Approved
Gadobenic acidPropofol may increase the QTc-prolonging activities of Gadobenic acid.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Propofol is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GemfibrozilThe metabolism of Propofol can be decreased when combined with Gemfibrozil.Approved
GemifloxacinPropofol may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Propofol is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Propofol is combined with Glutethimide.Approved, Illicit
GoserelinPropofol may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronPropofol may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Propofol is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Propofol.Approved, Illicit, Withdrawn
HaloperidolPropofol may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Propofol is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Propofol is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Propofol is combined with Hexobarbital.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Propofol.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Propofol.Approved, Vet Approved
HydrocodonePropofol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Propofol.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Propofol.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved
IbutilidePropofol may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Propofol can be increased when it is combined with Idelalisib.Approved
IloperidonePropofol may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Propofol.Approved, Investigational
ImatinibThe metabolism of Propofol can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Propofol.Investigational
ImipramineThe metabolism of Propofol can be decreased when combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Propofol is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Propofol.Approved
IndinavirThe metabolism of Propofol can be decreased when combined with Indinavir.Approved
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Propofol.Withdrawn
IrbesartanThe metabolism of Propofol can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Propofol.Approved, Investigational
IsavuconazoniumThe metabolism of Propofol can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Propofol.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Propofol.Approved, Vet Approved
IsoniazidThe metabolism of Propofol can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Propofol.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Propofol.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Propofol.Approved, Withdrawn
IsradipineThe metabolism of Propofol can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Propofol can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Propofol can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Propofol is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Propofol is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Propofol is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Propofol can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Propofol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Propofol.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Propofol is combined with Lamotrigine.Approved, Investigational
LapatinibThe metabolism of Propofol can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Propofol can be decreased when combined with Leflunomide.Approved, Investigational
LenvatinibPropofol may increase the QTc-prolonging activities of Lenvatinib.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Propofol.Approved, Investigational
LeuprolidePropofol may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Propofol is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Propofol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Propofol is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Propofol is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Propofol is combined with Levocetirizine.Approved
LevodopaPropofol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinPropofol may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Propofol is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Propofol is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Propofol is combined with Levorphanol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Propofol.Approved, Investigational
LidocaineThe metabolism of Propofol can be decreased when combined with Lidocaine.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Propofol.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Propofol is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Propofol is combined with Lofentanil.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Propofol.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Propofol.Approved
LopinavirThe metabolism of Propofol can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Propofol is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Propofol.Approved
LorcaserinThe metabolism of Propofol can be decreased when combined with Lorcaserin.Approved
LosartanThe metabolism of Propofol can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Propofol can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Propofol.Approved
LuliconazoleThe serum concentration of Propofol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Propofol can be increased when it is combined with Lumacaftor.Approved
LumefantrinePropofol may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Propofol is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Propofol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Propofol is combined with Maprotiline.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Propofol.Approved
MeclizineThe risk or severity of adverse effects can be increased when Propofol is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Propofol is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Propofol is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Propofol is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Propofol is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Propofol.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Propofol is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Propofol is combined with Metaxalone.Approved
MethadonePropofol may increase the QTc-prolonging activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Propofol is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Propofol is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Propofol is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Propofol.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Propofol is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Propofol.Approved
MethotrimeprazinePropofol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Propofol is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Propofol is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Propofol.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Propofol.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Propofol is combined with ECGONINE METHYL ESTER.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Propofol is combined with Methylphenobarbital.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Propofol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Propofol.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Propofol.Approved, Investigational
MetyrosinePropofol may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Propofol can be decreased when combined with Mexiletine.Approved
MidazolamThe serum concentration of Propofol can be increased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Propofol can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Propofol is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Propofol.Approved
MirabegronThe metabolism of Propofol can be decreased when combined with Mirabegron.Approved
MirtazapinePropofol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Propofol can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Propofol can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Propofol can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Propofol.Approved
MolindoneThe risk or severity of adverse effects can be increased when Propofol is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Propofol.Approved, Investigational
MoxifloxacinPropofol may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Propofol.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Propofol.Approved
NafcillinThe serum concentration of Propofol can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Propofol is combined with Nalbuphine.Approved
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Propofol.Approved, Investigational
NefazodoneThe metabolism of Propofol can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Propofol can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Propofol.Approved, Investigational
NetupitantThe serum concentration of Propofol can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Propofol can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Propofol can be decreased when combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Propofol.Approved
NicotineThe metabolism of Propofol can be decreased when combined with Nicotine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Propofol.Approved
NilotinibPropofol may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Propofol.Approved
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Propofol.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Propofol.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Nitrazepam.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Propofol.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Propofol.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Propofol.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Propofol.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Propofol is combined with Nitrous oxide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Propofol is combined with 1,1,1,2 Tetrafluoroethane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Propofol is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Propofol is combined with Nortriptyline.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Propofol.Approved
OfloxacinPropofol may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Propofol.Approved, Investigational
OlaparibThe metabolism of Propofol can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Propofol.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Propofol is combined with Olopatadine.Approved
OmeprazoleThe metabolism of Propofol can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronPropofol may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Propofol is combined with Opium.Approved, Illicit
OrphenadrinePropofol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Propofol is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Propofol can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Oxazepam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Propofol is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Propofol is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Propofol is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Propofol.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Propofol is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Propofol.Approved, Vet Approved
PalbociclibThe serum concentration of Propofol can be increased when it is combined with Palbociclib.Approved
PaliperidonePropofol may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatThe serum concentration of Propofol can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Propofol can be decreased when combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Propofol.Approved
ParaldehydePropofol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Propofol can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibPropofol may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Propofol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Propofol.Approved, Investigational
PentamidinePropofol may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Propofol.Approved, Vet Approved
PentobarbitalThe metabolism of Propofol can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved
PerazineThe risk or severity of adverse effects can be increased when Propofol is combined with Perazine.Investigational
PerflutrenPropofol may increase the QTc-prolonging activities of Perflutren.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Propofol.Approved
PerospironeThe risk or severity of adverse effects can be increased when Propofol is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Propofol is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Propofol.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Propofol.Approved
PhenobarbitalThe metabolism of Propofol can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Propofol.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Propofol is combined with Phenoxyethanol.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Propofol.Approved
PhenytoinThe metabolism of Propofol can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe serum concentration of Pimozide can be increased when it is combined with Propofol.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Propofol.Approved
PioglitazoneThe metabolism of Propofol can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Propofol is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Propofol is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Propofol is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Propofol is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Propofol is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Propofol can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexolePropofol may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Propofol is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Propofol.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Propofol.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Propofol.Approved
PrimaquinePropofol may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Propofol can be increased when combined with Primidone.Approved, Vet Approved
ProcainamidePropofol may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Propofol.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Propofol.Approved, Vet Approved
PromazinePropofol may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Propofol is combined with Promethazine.Approved
PropafenonePropofol may increase the QTc-prolonging activities of Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Propofol.Approved, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propofol is combined with Propoxycaine.Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Propofol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Propofol is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Propofol is combined with PSD502.Investigational
PyrimethamineThe metabolism of Propofol can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Propofol can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapinePropofol may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Propofol.Approved, Investigational
QuinidinePropofol may increase the QTc-prolonging activities of Quinidine.Approved
QuininePropofol may increase the QTc-prolonging activities of Quinine.Approved
RabeprazoleThe metabolism of Propofol can be decreased when combined with Rabeprazole.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Propofol is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Propofol is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Propofol.Approved
RanolazineThe metabolism of Propofol can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Propofol is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Propofol is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Propofol.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Propofol.Approved
RifabutinThe metabolism of Propofol can be increased when combined with Rifabutin.Approved
RifampicinRifampicin may increase the hypotensive activities of Propofol.Approved
RifapentineThe metabolism of Propofol can be increased when combined with Rifapentine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Propofol.Approved
RisperidonePropofol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Propofol is combined with Ritanserin.Investigational
RitonavirThe metabolism of Propofol can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Propofol can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Propofol is combined with Romifidine.Vet Approved
RopinirolePropofol may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be increased when it is combined with Propofol.Approved
RosiglitazoneThe metabolism of Propofol can be decreased when combined with Rosiglitazone.Approved, Investigational
RotigotinePropofol may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Propofol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Propofol is combined with Sacubitril.Approved
SaquinavirThe metabolism of Propofol can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Propofol is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Propofol can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Propofol is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Propofol is combined with Uc1010.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Propofol is combined with Sertindole.Approved, Withdrawn
SertralineThe metabolism of Propofol can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Propofol is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Propofol can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Propofol can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Propofol can be increased when it is combined with Simeprevir.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Propofol is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved
SorafenibThe metabolism of Propofol can be decreased when combined with Sorafenib.Approved, Investigational
SotalolPropofol may increase the QTc-prolonging activities of Sotalol.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Propofol.Approved
St. John's WortThe serum concentration of Propofol can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Propofol can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Propofol is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Propofol.Approved, Investigational
SulfadiazineThe metabolism of Propofol can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Propofol can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Propofol can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Propofol.Approved
SuvorexantPropofol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamoxifenThe metabolism of Propofol can be decreased when combined with Tamoxifen.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Propofol is combined with Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Propofol is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Propofol is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Propofol can be decreased when combined with Telaprevir.Withdrawn
TelavancinPropofol may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Propofol can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Propofol.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Propofol.Approved
Tenofovir disoproxilThe metabolism of Propofol can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Propofol.Approved
TerbinafineThe metabolism of Propofol can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe serum concentration of Propofol can be decreased when it is combined with Teriflunomide.Approved
TetrabenazinePropofol may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Propofol is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Propofol is combined with Tetrodotoxin.Investigational
ThalidomidePropofol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Propofol can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Propofol is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Propofol.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Propofol.Withdrawn
ThiotepaThe metabolism of Propofol can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Propofol is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Propofol is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Propofol is combined with Tiapride.Approved, Investigational
TicagrelorThe metabolism of Propofol can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Propofol can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Propofol is combined with Tiletamine.Vet Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Propofol.Approved
TipranavirThe metabolism of Propofol can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Propofol.Approved
TocilizumabThe serum concentration of Propofol can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Propofol is combined with Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Propofol can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Propofol is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Propofol is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Propofol.Approved
ToremifenePropofol may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Propofol.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Propofol.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Propofol is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Propofol can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Propofol.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Propofol is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Propofol.Approved
TriazolamThe risk or severity of adverse effects can be increased when Propofol is combined with Triazolam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Propofol is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Propofol.Approved, Vet Approved
TrimethoprimThe metabolism of Propofol can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Propofol is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Propofol is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Propofol.Approved, Investigational
ValsartanThe metabolism of Propofol can be decreased when combined with Valsartan.Approved, Investigational
VandetanibPropofol may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibThe serum concentration of Propofol can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Propofol can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Propofol can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Propofol is combined with Vigabatrin.Approved
VoriconazoleThe metabolism of Propofol can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Propofol is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Propofol is combined with Xylazine.Vet Approved
ZafirlukastThe metabolism of Propofol can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Propofol is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Propofol is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Propofol is combined with Zimelidine.Withdrawn
ZiprasidonePropofol may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Propofol is combined with Zolazepam.Vet Approved
ZolpidemPropofol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Propofol is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Propofol is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Propofol is combined with Zotepine.Approved
ZuclopenthixolPropofol may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

John R. Carpenter, "Propofol-based anesthetic and method of making same." U.S. Patent US6150423, issued May, 1977.

US6150423
General References
  1. Vasile B, Rasulo F, Candiani A, Latronico N: The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med. 2003 Sep;29(9):1417-25. Epub 2003 Aug 6. [PubMed:12904852 ]
  2. Ke JJ, Zhan J, Feng XB, Wu Y, Rao Y, Wang YL: A comparison of the effect of total intravenous anaesthesia with propofol and remifentanil and inhalational anaesthesia with isoflurane on the release of pro- and anti-inflammatory cytokines in patients undergoing open cholecystectomy. Anaesth Intensive Care. 2008 Jan;36(1):74-8. [PubMed:18326136 ]
  3. Hong JY, Kang YS, Kil HK: Anaesthesia for day case excisional breast biopsy: propofol-remifentanil compared with sevoflurane-nitrous oxide. Eur J Anaesthesiol. 2008 Jun;25(6):460-7. doi: 10.1017/S026502150800375X. Epub 2008 Feb 26. [PubMed:18298873 ]
External Links
ATC CodesN01AX10 — Propofol
AHFS Codes
  • 28:04.92
PDB EntriesNot Available
FDA labelDownload (168 KB)
MSDSDownload (71.9 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingPreventionFemur Head Necrosis1
1Active Not RecruitingBasic ScienceHealthy Volunteers1
1CompletedNot AvailableAdjunct to general anesthesia therapy2
1CompletedBasic ScienceAdjunct to general anesthesia therapy1
1CompletedDiagnosticAdjunct to general anesthesia therapy1
1CompletedHealth Services ResearchDyssomnias / Sleep Disorder / Sleeplessness1
1CompletedTreatmentAmnesia-Memory Loss / Memory Losses1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentInflammatory Reaction2
1CompletedTreatmentLactating Women1
1CompletedTreatmentMonitored anesthesia care sedation1
1Enrolling by InvitationTreatmentMajor Depressive Disorder (MDD)1
1RecruitingBasic ScienceAnaesthesia therapy / Renal Failure1
1RecruitingTreatmentAnesthesia Intubation Complications / Other Preterm Infants / Premature Birth of Newborn / Propofol Overdose1
1Unknown StatusNot AvailableAnaesthesia therapy / Magnetic Resonance Imaging (MRI)1
1, 2CompletedDiagnosticAnaesthesia therapy1
1, 2CompletedTreatmentBrain Injury / Intracranial Pressure1
1, 2CompletedTreatmentMyocardial Reperfusion Injury / Nonvalvular Atrial Fibrillation1
1, 2CompletedTreatmentRadical Mastectomy1
1, 2CompletedTreatmentShock, Septic1
1, 2Not Yet RecruitingPreventionInflammatory Lung Injury / Ischemia-Reperfusion Lung Injury / Postoperative Pulmonary Complications1
1, 2Unknown StatusTreatmentComplications1
1, 2Unknown StatusTreatmentPostoperative pain1
1, 2WithdrawnOtherActive Emergence From General Anesthesia1
2CompletedNot AvailableArterial Hypotension1
2CompletedNot AvailableAdjunct to general anesthesia therapy1
2CompletedOtherSedation therapy1
2CompletedPreventionStrabismus1
2CompletedTreatmentAdverse Reaction to Drug / Neonatal Disorder1
2CompletedTreatmentAnaesthesia therapy / Coronary Artery Disease1
2CompletedTreatmentAnaesthesia therapy / Hysterectomy / Ketamine / Morphine1
2CompletedTreatmentAnalgesic Rebound Headache / Chronic Daily Headache / Chronic Headaches / Headache, Intractable1
2CompletedTreatmentAnesthetics1
2CompletedTreatmentCoronary Artery Bypass Grafting (CABG) Surgery1
2CompletedTreatmentCoronary Artery Bypass Surgery / Ischemic Coronary Artery Disease1
2CompletedTreatmentEndoscopy, Gastrointestinal / Gastrointestinal Polypectomy1
2CompletedTreatmentKnee Replacement Surgery / Orthopedic Procedures / Total Hip Prosthesis1
2CompletedTreatmentSedation therapy1
2CompletedTreatmentAdjunct to general anesthesia therapy1
2RecruitingPreventionCholangitis / Pancreatitis1
2RecruitingSupportive CareCancer, Breast1
2RecruitingTreatmentSubarachnoid Haemorrhage (SAH)1
2WithdrawnSupportive CarePatients With "ASA 3" Designation / Patients With ASA 3 Designation1
2WithdrawnSupportive CareTraumatic Brain Injury (TBI)1
2, 3Active Not RecruitingTreatmentCerebral Hypoperfusion / Intubation, Endotracheal / Premedication1
2, 3Active Not RecruitingTreatmentIntubation, Endotracheal / Premedication1
2, 3CompletedPreventionPain1
2, 3CompletedTreatmentMigrainous Headache1
2, 3CompletedTreatmentMyocardial Injury1
2, 3CompletedTreatmentTraumas1
2, 3RecruitingPreventionRefractory Epilepsy1
2, 3RecruitingTreatmentNeoplasms, Lung1
2, 3Unknown StatusTreatmentAwake Fiberoptic Nasal Intubation1
2, 3Unknown StatusTreatmentObesity, Morbid1
2, 3WithdrawnSupportive CareLeukemias1
3CompletedNot AvailableSedation therapy1
3CompletedDiagnosticCancer, Breast1
3CompletedPreventionAnaesthesia therapy2
3CompletedPreventionCranitomy Surgery1
3CompletedPreventionLaryngospasm1
3CompletedSupportive CareRespiratory Insufficiency1
3CompletedTreatmentAbscess Incision and Drainage / Electrical Cardioversion / Emergency Department Procedural Sedation / Fractures Reduction1
3CompletedTreatmentAnaesthesia therapy1
3CompletedTreatmentAnaesthesia therapy / Craniotomy / Neurosurgery1
3CompletedTreatmentAnesthesia With Use of LMA (Laryngeal Mask Airway)1
3CompletedTreatmentCerebral Aneurysms / Cerebral Arterial Diseases1
3CompletedTreatmentContinuous Sedation in Initially Sedated Adults in ICU1
3CompletedTreatmentCoronary Artery Bypass Graft Surgery / Coronary Artery Disease / General Anesthetic Drug Allergy1
3CompletedTreatmentElective Caesarean Section Surgeries1
3CompletedTreatmentAdjunct to general anesthesia therapy / Elective Surgery1
3CompletedTreatmentEnd-stage Chronic Renal Disease / Severe Acute Kidney Failure / Transplantation, Renal1
3CompletedTreatmentGeneral Anaesthesia / Induction of Anaesthesia1
3CompletedTreatmentHepatectomy1
3CompletedTreatmentAdjunct to general anesthesia therapy / Intravenous Anesthesia1
3CompletedTreatmentMuscle Relaxation1
3CompletedTreatmentSedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy1
3CompletedTreatmentSpinal Puncture1
3Not Yet RecruitingTreatmentAcute Appendicitis / Inguinal Hernias1
3RecruitingPreventionDelirium / Impaired Cognition / Sepsis1
3RecruitingPreventionNeoplasms, Breast1
3RecruitingSupportive CareAnaesthesia / Children / Heart Diseases / Magnetic Resonance Imaging (MRI)1
3RecruitingSupportive CareMalignant Neoplasms of Male Genital Organs1
3RecruitingSupportive CarePreoperative Sedation1
3RecruitingTreatmentStrokes1
3TerminatedTreatmentAnaesthesia therapy1
3TerminatedTreatmentAnalgesia1
3TerminatedTreatmentBone Marrow Diseases / Pain1
3TerminatedTreatmentSafety and Efficacy of Sedation Medications1
3TerminatedTreatmentSubarachnoid Hemorrhage, Aneurysmal1
3TerminatedTreatmentTraumatic Brain Injury (TBI)1
3TerminatedTreatmentRefractory seizure disorders1
3Unknown StatusTreatmentIntubation, Endotracheal1
3WithdrawnNot AvailableHypertensive1
4Active Not RecruitingNot AvailableCardiac Diseases1
4Active Not RecruitingPreventionAlcohol Drinking / Dexmedetomidine / Lumbar epidural anesthesia therapy / Propofol / Sedation, Conscious / Spinal Anaesthesia1
4Active Not RecruitingTreatmentComplications1
4Active Not RecruitingTreatmentCritical Illness1
4Active Not RecruitingTreatmentDriving Performance After Minor Ambulatory Surgery / Minor Surgical Procedures With Monitored Anesthesia Care1
4Active Not RecruitingTreatmentPostoperative pain1
4CompletedNot AvailableAsthma Bronchial1
4CompletedNot AvailableDigestive System Diseases / Disorientation1
4CompletedNot AvailableDisorders of Gallbladder, Biliary Tract and Pancrease1
4CompletedNot AvailableFailed Moderate Sedation During Procedure1
4CompletedNot AvailableIdiopathic Scoliosis / Neuromuscular Dystrophy / Spine Deformity1
4CompletedNot AvailableInflammatory Reaction1
4CompletedNot AvailablePatients Requiring Ambulatory Surgery Under General Anesthesia1
4CompletedNot AvailableShoulder Pain1
4CompletedBasic ScienceAnaesthesia therapy1
4CompletedBasic ScienceAnaesthesia therapy / Loss of Consciousness1
4CompletedBasic ScienceConsciousness, Level Altered1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedBasic SciencePropofol-anaesthesia Via Target-controlled Infusion1
4CompletedDiagnosticAlteration of Cognitive Function / Gastrointestinal Dysfunction1
4CompletedDiagnosticAnaesthesia1
4CompletedDiagnosticAnaesthesia therapy / Electroencephalography/ Drug Effect1
4CompletedDiagnosticPulmonary Hypertension (PH)1
4CompletedHealth Services ResearchAnesthesia Intubation Complications1
4CompletedHealth Services ResearchHealthy Volunteers1
4CompletedPreventionAirway Complication of Anaesthesia / Healthy Volunteers1
4CompletedPreventionAnaesthesia therapy / Palonosetron / Ponv1
4CompletedPreventionAnaesthesia therapy / Surgery, Cardiac1
4CompletedPreventionChronic Rhinosinusitis1
4CompletedPreventionCognitive Impairments1
4CompletedPreventionCoronary Artery Disease1
4CompletedPreventionDegenerative Arthritis1
4CompletedPreventionDelirium1
4CompletedPreventionElective Orthopedic Surgery1
4CompletedPreventionHeart Valve Disease1
4CompletedPreventionHemodynamics Instability / Renal Function Disorder1
4CompletedPreventionInduction of Anaesthesia1
4CompletedPreventionPostoperative Cognitive Functions1
4CompletedPreventionPostoperative Confusion1
4CompletedPreventionPregnancy1
4CompletedPreventionProstate Cancer1
4CompletedPreventionSublingual Microcirculation1
4CompletedPreventionSupratentorial Neoplasms1
4CompletedPreventionTotal Knee Arthroplasty (TKA) / Tourniquet-Induced Ischemia-Reperfusion Injury1
4CompletedPreventionUpper Respiratory Infections1
4CompletedScreeningAnaesthesia therapy / Neuromuscular Blockade1
4CompletedScreeningHemodynamics / Side Effects1
4CompletedSupportive CareBMI >30 kg/m22
4CompletedSupportive CareCoronary Artery Disease1
4CompletedSupportive CareDNA Damage / Patients in Good Health / Types of General Anesthesia1
4CompletedSupportive CareEnd Stage Renal Disease (ESRD) / Healthy Volunteers1
4CompletedSupportive CareHypothermia1
4CompletedSupportive CareHysterectomy (MeSH nr: E04.950.300.399)1
4CompletedSupportive CareIBS / Malignant Neoplasm of Colon / Polyps1
4CompletedSupportive CareIntravenous Anesthetic Interaction "Unrecognized Condition" / Intravenous Anesthetic Interaction Unrecognized Condition1
4CompletedSupportive CareNausea / Tiredness1
4CompletedSupportive CareParkinson's Disease (PD)1
4CompletedSupportive CarePatients in Good Health1
4CompletedSupportive CarePostoperative pain / Prophylaxis against postoperative nausea and vomiting1
4CompletedSupportive CareRobotic Thyroidectomy1
4CompletedSupportive CareTranscervical Resection of Endometrium / Transcervical Resection of Fibroids / Transcervical Resection of Polyp1
4CompletedTreatmentAbdominal / Aneurysms / Aortic Diseases / General Surgery1
4CompletedTreatmentAbnormal Respiratory Airway Resistance1
4CompletedTreatmentAgeing / Induction of Anaesthesia1
4CompletedTreatmentAmbulatory Surgery / Anaesthesia therapy / Energy Expenditure / Food Intake1
4CompletedTreatmentAnaesthesia therapy4
4CompletedTreatmentAnaesthesia therapy / General Surgery1
4CompletedTreatmentArthritis / BMI >30 kg/m21
4CompletedTreatmentBrain Diseases1
4CompletedTreatmentBronchoscopy1
4CompletedTreatmentCarotid Stenosis1
4CompletedTreatmentCataracts1
4CompletedTreatmentComplication of Injection / Pain2
4CompletedTreatmentCoronary Artery Disease / Mitral Valve Regurgitation1
4CompletedTreatmentCoronary Artery Disease / Off Pump Coronary Artery Bypass Surgery1
4CompletedTreatmentCoronary Artery Disease / Valvular Heart Disease1
4CompletedTreatmentDeep Sedation / Delayed Emergence From Anesthesia1
4CompletedTreatmentDelayed Emergence From Anesthesia1
4CompletedTreatmentDepressive State1
4CompletedTreatmentDisorder; Mental, Sedative / General Surgery / Postoperative pain1
4CompletedTreatmentDisorders of Gallbladder, Biliary Tract and Pancreas1
4CompletedTreatmentDrug Safety / Procedural Sedation1
4CompletedTreatmentDrug Usage1
4CompletedTreatmentEfficacy and Safety of Mivacurium Chloride for Pediatric Patients1
4CompletedTreatmentElective Laparoscopic Surgery1
4CompletedTreatmentEmergence Agitation1
4CompletedTreatmentEndoscopic Retrograde Cholangiopancreatography1
4CompletedTreatmentEndoscopy, Gastrointestinal / Moderate Sedation / Propofol / Target Controlled Infusion (TCI)1
4CompletedTreatmentEndoscopy / Inflammatory Bowel Diseases (IBD) / Sedation therapy1
4CompletedTreatmentEndoscopy / Sedation therapy1
4CompletedTreatmentGall Stone Disease1
4CompletedTreatmentGynecological Disease / Healthy Adults1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHypnosis1
4CompletedTreatmentHypoxemia1
4CompletedTreatmentHysterectomy1
4CompletedTreatmentHysteroscopic Surgery / Surgery, Laparoscopic1
4CompletedTreatmentInduction of Anaesthesia1
4CompletedTreatmentInguinal Hernias / Undescended Testis1
4CompletedTreatmentLung Cancers1
4CompletedTreatmentLung Function1
4CompletedTreatmentObesity, Morbid1
4CompletedTreatmentObstructive Sleep Apnea (OSA)1
4CompletedTreatmentPediatric Rigid Bronchoscopy1
4CompletedTreatmentPharmacodynamic Interaction1
4CompletedTreatmentPostoperative Sleep Quality1
4CompletedTreatmentProcedural Sedation2
4CompletedTreatmentPulmonary Resection1
4CompletedTreatmentRetinal Disorders1
4CompletedTreatmentRetinal Surgery1
4CompletedTreatmentSedation therapy6
4CompletedTreatmentSedation, Conscious1
4CompletedTreatmentSepsis / Shock, Septic / Systemic Inflammatory Response Syndrome (SIRS)1
4CompletedTreatmentSleep Apnea, Obstructive1
4CompletedTreatmentStrokes / Subarachnoid Hemorrhage1
4CompletedTreatmentSubfertility1
4CompletedTreatmentSupraglottic Airways for General Anesthesia1
4CompletedTreatmentSurgery, Cardiac1
4CompletedTreatmentThoracic Surgery1
4CompletedTreatmentTopical Anesthesia1
4CompletedTreatmentTreatment Resistant Depression (TRD)1
4CompletedTreatmentSynovitis of osteoarthritis1
4Enrolling by InvitationPreventionAnesthesia, Intratracheal / Hernia / Intravenous Anesthesia / Pain, Acute / Pain, Chronic1
4Enrolling by InvitationSupportive CareHemodynamics Instability1
4Enrolling by InvitationSupportive CarePostoperative; Dysfunction Following Cardiac Surgery1
4Enrolling by InvitationSupportive CareSmooth muscle relaxation prior to radiological procedures1
4Enrolling by InvitationTreatmentAnalgesia, Patient-Controlled / Arthroplasty / Gastric Resection1
4Enrolling by InvitationTreatmentAnesthesia Complication / Hemodynamics Instability / Ileus paralytic / Nausea / Postoperative pain / Vomiting1
4Enrolling by InvitationTreatmentAnesthesia Morbidity / Children1
4Enrolling by InvitationTreatmentComplications / Delirium / Ventilations, Mechanical1
4Not Yet RecruitingBasic ScienceAnesthesia; Bariatric Surgery1
4Not Yet RecruitingBasic ScienceMicrocirculation1
4Not Yet RecruitingDiagnosticGlycogen Synthase Kinase 31
4Not Yet RecruitingPreventionC.Surgical Procedure; Cardiac / Delirium1
4Not Yet RecruitingSupportive CareAnaesthesia therapy1
4Not Yet RecruitingSupportive CareCognition Disorders in Old Age1
4Not Yet RecruitingSupportive CareColonoscopy1
4Not Yet RecruitingTreatmentAnaesthesia therapy / Electroconvulsive Therapy1
4Not Yet RecruitingTreatmentCritical Illness / Deep Sedation / Ventilators, Mechanical1
4Not Yet RecruitingTreatmentDelirium1
4Not Yet RecruitingTreatmentDelirium / Hemodynamics Instability1
4Not Yet RecruitingTreatmentGynecology / Surgery, Laparoscopic1
4Not Yet RecruitingTreatmentInfertility, Female / Postoperative pain1
4Not Yet RecruitingTreatmentIntra-Abdominal Hypertension1
4RecruitingNot AvailableAnaesthesia therapy / This is a Pharmacokinetics Study (no Specific Condition is Studied)1
4RecruitingNot AvailableGeneral Surgery1
4RecruitingNot AvailableHeart Septal Defects, Atrial / Heart Valve Disease1
4RecruitingBasic ScienceSevere Sepsis1
4RecruitingDiagnosticBispectral Index / Induction of anesthesia therapy / Target Controlled Infusion (TCI)1
4RecruitingDiagnosticLiver Diseases1
4RecruitingPreventionCoronary Artery Bypass Graft Redo / General Anesthetic Drug Adverse Reaction1
4RecruitingPreventionDelirium / Postoperative Cognitive Dysfunction / Postoperative Complications1
4RecruitingPreventionEmergence Agitation1
4RecruitingPreventionEndovascular Repair of Aortic Aneurysm / Endovascular Treatment of Arteriosclerosis Obliterans of Lower Extremities1
4RecruitingPreventionIntra-abdominal and Intrapelvic Surgery / Intra-abdominal Surgery1
4RecruitingPreventionLong-Term Effects Secondary to Cancer Therapy in Adults1
4RecruitingPreventionPostoperative Cognitive Dysfunction1
4RecruitingPreventionAdjunct to general anesthesia therapy / Surgical Oncology1
4RecruitingPreventionVascular Surgery1
4RecruitingSupportive CareAcute Subdural Hematoma1
4RecruitingSupportive CareAnesthesia, Conduction / Drug Interactions1
4RecruitingSupportive CareAnesthesia, Intravenous; Surgery, Plastic1
4RecruitingSupportive CareBariatrics / BMI >30 kg/m2 / Bypass, Gastric / Endoscopy / Sleep Apnea Syndromes1
4RecruitingSupportive CareBehaviors / Cognitive Change1
4RecruitingSupportive CareColonic Neoplasms / Neoplasms, Breast / Rectal Neoplasms1
4RecruitingTreatmentAcute Agitation / Respiratory Failure / Sepsis1
4RecruitingTreatmentAdvanced Chronic Rhinosinusitis1
4RecruitingTreatmentAmnestic / Cognitive Disorders / Delirium / Dementias1
4RecruitingTreatmentAnaesthesia therapy / Delirium / Hip Fractures1
4RecruitingTreatmentArteriovenous Fistulas1
4RecruitingTreatmentCardiac Arrest / Hypothermia1
4RecruitingTreatmentCesarean Section / Propofol / Sevoflurane1
4RecruitingTreatmentDelirium2
4RecruitingTreatmentFemale Breast Carcinoma1
4RecruitingTreatmentOxygenation During One Lung Ventilation1
4RecruitingTreatmentPain2
4RecruitingTreatmentPatients Ongoing Elective Abdominal Laparoscopy1
4RecruitingTreatmentPost-operative Residual Curarization1
4TerminatedPreventionDelirium on Emergence1
4TerminatedSupportive CarePain1
4TerminatedTreatmentAnaesthesia therapy1
4TerminatedTreatmentAnesthesia Recovery Period / Postoperative pain1
4Unknown StatusNot AvailableHealthy Volunteers1
4Unknown StatusDiagnosticCognitive Impairments1
4Unknown StatusDiagnosticHealthy Volunteers1
4Unknown StatusDiagnosticObesity, Morbid1
4Unknown StatusDiagnosticSafety of Gastroscopy1
4Unknown StatusDiagnosticUGT1A1*28 Polymorphism1
4Unknown StatusPreventionCerebral Hypoxia / Postoperative Delirium1
4Unknown StatusPreventionCognition Disorders1
4Unknown StatusPreventionDelirium1
4Unknown StatusPreventionAdjunct to general anesthesia therapy / Geriatric Patients1
4Unknown StatusSupportive CareProcedural Sedation / Propofol1
4Unknown StatusSupportive CareRespiratory Distress Syndrome (RDS)1
4Unknown StatusTreatmentAnaesthesia therapy1
4Unknown StatusTreatmentAnaesthesia therapy / Hemodynamics / Oxidative Stress1
4Unknown StatusTreatmentAnaesthesia therapy / Pregnancy Termination1
4Unknown StatusTreatmentBispectral Index / Etomidate / Induction / Pediatric1
4Unknown StatusTreatmentCongenital Choledochal Cyst / Congenital Hydronephrosis / Fracture Bone1
4Unknown StatusTreatmentConscious Sedation Failure During Procedure1
4Unknown StatusTreatmentCritical Illness / Ventilations, Mechanical1
4Unknown StatusTreatmentDelirium1
4Unknown StatusTreatmentDepressive Symptoms / Electroconvulsive Therapy / Impaired Cognition1
4Unknown StatusTreatmentDisorder; Heart, Functional, Postoperative, Cardiac Surgery / Heart; Dysfunction Postoperative, Cardiac Surgery1
4Unknown StatusTreatmentEmergency1
4Unknown StatusTreatmentHemodynamics / Hysteroscopy / Sedation therapy1
4Unknown StatusTreatmentHepatic Encephalopathy1
4Unknown StatusTreatmentHyperalgesia1
4Unknown StatusTreatmentLiver Cirrhosis1
4Unknown StatusTreatmentMechanical Ventilation Complication1
4Unknown StatusTreatmentPatients Undergoing Elective Craniotomy1
4Unknown StatusTreatmentAdjunct to general anesthesia therapy / Target Controlled Infusion (TCI)1
4WithdrawnPreventionMemory Disorders / Other Functional Disturbances Following Cardiac Surgery1
4WithdrawnSupportive CareAlcoholism / Respiration, Artificial1
4WithdrawnTreatmentSleep1
Not AvailableActive Not RecruitingNot AvailableAortic Valve Stenosis1
Not AvailableActive Not RecruitingNot AvailableLung Cancers1
Not AvailableActive Not RecruitingNot AvailableObesity, Morbid1
Not AvailableActive Not RecruitingBasic ScienceBrain Activity Under Sedation1
Not AvailableActive Not RecruitingDiagnosticAmnesic Properties of Propofol / Pediatric Pateints1
Not AvailableActive Not RecruitingDiagnosticBMI >30 kg/m21
Not AvailableActive Not RecruitingOtherSleep disorders and disturbances1
Not AvailableActive Not RecruitingPreventionIschemic Optic Neuropathy1
Not AvailableActive Not RecruitingTreatmentFracture Bone / Pain1
Not AvailableCompletedNot AvailableAnaesthesia therapy2
Not AvailableCompletedNot AvailableAnaesthesia therapy / Effects of Dexmedetomidine / Elderly Patients / Emergence From Anesthesia / Recovery From Anesthesia1
Not AvailableCompletedNot AvailableAnesthesia; Functional / Heart Rate Low1
Not AvailableCompletedNot AvailableBlindness1
Not AvailableCompletedNot AvailableBlood Flow / Brain Oxygenation / Deep Brain Stimulation (DBS) / Intracranial Neurosurgery1
Not AvailableCompletedNot AvailableCardioprotection / Hepatic Function / Recovery From Sedation / Renal Function / Sevoflurane Consumption1
Not AvailableCompletedNot AvailableChronic Constipation1
Not AvailableCompletedNot AvailableDepth of Anesthesia (DOA)1
Not AvailableCompletedNot AvailableEndoscopy1
Not AvailableCompletedNot AvailableEpilepsies1
Not AvailableCompletedNot AvailableFunctional Dyspepsia / Gastritis1
Not AvailableCompletedNot AvailableGender1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailableHorner's Syndrome1
Not AvailableCompletedNot AvailableIgel1
Not AvailableCompletedNot AvailableLiver Dysfunction1
Not AvailableCompletedNot AvailableNeuromuscular Monitoring1
Not AvailableCompletedNot AvailableObstructive Sleep Apnea (OSA)1
Not AvailableCompletedNot AvailableOrthopedics1
Not AvailableCompletedNot AvailablePain1
Not AvailableCompletedNot AvailableRenal Failure1
Not AvailableCompletedNot AvailableRhytidoplasty1
Not AvailableCompletedNot AvailableRotator Cuff Tear Arthropathy1
Not AvailableCompletedBasic ScienceAnaesthesia therapy1
Not AvailableCompletedBasic ScienceDrug Interaction Potentiation1
Not AvailableCompletedBasic ScienceSaccadic Eye Movements1
Not AvailableCompletedBasic ScienceAdjunct to general anesthesia therapy1
Not AvailableCompletedDiagnosticConscious Sedation Failure During Procedure1
Not AvailableCompletedDiagnosticEGD Procedure1
Not AvailableCompletedDiagnosticSedation therapy1
Not AvailableCompletedHealth Services ResearchPropofol Pharmacokinetics1
Not AvailableCompletedOtherObese1
Not AvailableCompletedPreventionAdverse Effects1
Not AvailableCompletedPreventionAnaesthesia therapy1
Not AvailableCompletedPreventionAnaesthesia therapy / Catheter Site Discomfort / Complications / Urinary Bladder Neoplasms1
Not AvailableCompletedPreventionBlood Pressures1
Not AvailableCompletedPreventionCardiac Diseases / Delirium1
Not AvailableCompletedPreventionEnd-stage Liver Disease (ESLD)1
Not AvailableCompletedPreventionGeneral Surgery1
Not AvailableCompletedPreventionGeneral Surgery / Prostate Cancer1
Not AvailableCompletedPreventionIschemia, Cerebral1
Not AvailableCompletedPreventionOesophagitis, Eosinophilic1
Not AvailableCompletedPreventionPain2
Not AvailableCompletedPreventionThoracic Surgery With One-lung Ventilation1
Not AvailableCompletedPreventionVitrectomy Operation Under General Anesthesia1
Not AvailableCompletedPreventionVocal Cord; Injury, Superficial1
Not AvailableCompletedScreeningCerebral Palsy (CP)1
Not AvailableCompletedScreeningElectroconvulsive Therapy / Physiatrics1
Not AvailableCompletedScreeningMetabolic Acidosis1
Not AvailableCompletedSupportive CareAnaesthesia therapy / Body Temperature Changes1
Not AvailableCompletedSupportive CareAnaesthesia therapy / Local Anesthesia1
Not AvailableCompletedSupportive CareAnesthesia Intubation Complications1
Not AvailableCompletedSupportive CareBipolar Disorder (BD) / Major Depressive Disorder (MDD) / Schizophrenic Disorders1
Not AvailableCompletedSupportive CareC.Delivery; Surgery (Previous), Gynecological / Delayed Emergence From Anesthesia / Inappropriate Device Stimulation of Tissue1
Not AvailableCompletedSupportive CareCataracts / Corneal Inflammation / Pterygium / Retina Detachment / Vitreous Hemorrhage1
Not AvailableCompletedSupportive CareChildren1
Not AvailableCompletedSupportive CareConscious Sedation Under Spinal Anesthesia1
Not AvailableCompletedSupportive CareDriving1
Not AvailableCompletedSupportive CareEndarterectomy / Postoperative Cognitive Dysfunction1
Not AvailableCompletedSupportive CareIdiopathic Scoliosis1
Not AvailableCompletedSupportive CareIntraocular Pressure1
Not AvailableCompletedSupportive CareLiver Cirrhosis1
Not AvailableCompletedSupportive CarePain1
Not AvailableCompletedSupportive CarePediatric Urinary Disorders1
Not AvailableCompletedTreatmentAmnesia / Cognition Disorders / Coronary Artery Bypass Graft / Delirium / Dementias / Morbidity1
Not AvailableCompletedTreatmentAnaesthesia therapy1
Not AvailableCompletedTreatmentAnaesthesia therapy / Bispectral Index Monitoring / Delirium / Dementias1
Not AvailableCompletedTreatmentAnaesthesia therapy / Immunotoxicity / Inert Gas Narcosis1
Not AvailableCompletedTreatmentAnaesthesia therapy / Neuromuscular Blockade1
Not AvailableCompletedTreatmentBlood Loss1
Not AvailableCompletedTreatmentCardiac On-pump Surgery1
Not AvailableCompletedTreatmentCervical Spondylosis / Lumbar Spondylosis / Osteoarthritis of the Knees / Osteoarthritis, Hip1
Not AvailableCompletedTreatmentChronic Lung Diseases1
Not AvailableCompletedTreatmentColonoscopy1
Not AvailableCompletedTreatmentComplication of Gastrostomy1
Not AvailableCompletedTreatmentDrug Usage1
Not AvailableCompletedTreatmentElective Surgery / Healthy Volunteers1
Not AvailableCompletedTreatmentEmergence Delirium1
Not AvailableCompletedTreatmentFractures, Compression1
Not AvailableCompletedTreatmentIschaemic Heart Diseases1
Not AvailableCompletedTreatmentMajor Depressive Disorder (MDD)1
Not AvailableCompletedTreatmentMechanical Ventilation Complication1
Not AvailableCompletedTreatmentMyocardial Repolarization1
Not AvailableCompletedTreatmentNeoplasms, Brain1
Not AvailableCompletedTreatmentPain1
Not AvailableCompletedTreatmentPostoperative pain2
Not AvailableCompletedTreatmentPregnancy Termination / Uterine Curettage1
Not AvailableCompletedTreatmentRespiration Disorders1
Not AvailableCompletedTreatmentRespiratory Insufficiency1
Not AvailableCompletedTreatmentSedation therapy1
Not AvailableCompletedTreatmentSepsis / Shock1
Not AvailableCompletedTreatmentTracheal Intubation1
Not AvailableCompletedTreatmentSynovitis of osteoarthritis1
Not AvailableEnrolling by InvitationPreventionChildren / Transplantation, Liver1
Not AvailableEnrolling by InvitationPreventionPostoperative Delirium1
Not AvailableEnrolling by InvitationScreeningAnaesthesia therapy / General Surgery / Ophthalmic1
Not AvailableNot Yet RecruitingNot AvailableAnaesthesia therapy1
Not AvailableNot Yet RecruitingNot AvailableCardiovascular Surgical Procedures1
Not AvailableNot Yet RecruitingNot AvailableGeneral Anesthetics Toxicity / Lymphocyte Destruction / Metastatic Colorectal Cancers / Molecular Mechanism of Pharmacological Action / Survival Rate1
Not AvailableNot Yet RecruitingNot AvailableSex / TOF1
Not AvailableNot Yet RecruitingBasic ScienceNon-Small-Cell Lung Carcinoma (NSCLC)1
Not AvailableNot Yet RecruitingPreventionNausea and Vomiting1
Not AvailableNot Yet RecruitingPreventionTransplantation, Liver1
Not AvailableNot Yet RecruitingSupportive CareDexmedetomidine1
Not AvailableNot Yet RecruitingSupportive CareFemale Breast Cancer1
Not AvailableNot Yet RecruitingSupportive CareNeoplasms, Brain1
Not AvailableNot Yet RecruitingTreatmentAcute Rejection in Kidney Transplantation / Renal Outcome After Kidney Transplantation1
Not AvailableNot Yet RecruitingTreatmentAnaesthesia therapy1
Not AvailableNot Yet RecruitingTreatmentC.Delivery; Surgery (Previous), Gynecological1
Not AvailableNot Yet RecruitingTreatmentColonic Neoplasms1
Not AvailableNot Yet RecruitingTreatmentObesity, Morbid1
Not AvailableNot Yet RecruitingTreatmentPostoperative Complications1
Not AvailableNot Yet RecruitingTreatmentPostoperative Recovery / Transurethral Resection of the Bladder / Urinary Bladder Neoplasms1
Not AvailableNot Yet RecruitingTreatmentAdjunct to general anesthesia therapy2
Not AvailableRecruitingNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / Hospital-acquired bacterial pneumonia / Hypercholesterolaemia / Hyperlipidemias / Hypertensive / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal1
Not AvailableRecruitingNot AvailableAnaesthesia therapy1
Not AvailableRecruitingNot AvailableGliomas1
Not AvailableRecruitingNot AvailableInhalation and Intravenous Anesthesia / Microcirculatory Effects of Anesthesia1
Not AvailableRecruitingNot AvailableIntravenous Anesthetic Agent Overdose1
Not AvailableRecruitingNot AvailablePituitary Adenomas1
Not AvailableRecruitingNot AvailablePostoperative pain1
Not AvailableRecruitingNot AvailableShort Stature1
Not AvailableRecruitingBasic ScienceCancer, Breast2
Not AvailableRecruitingBasic ScienceMalignant Neoplasm of Colon1
Not AvailableRecruitingBasic SciencePain1
Not AvailableRecruitingBasic ScienceSomatosensory Evoked Potentials, and Electroencephalography1
Not AvailableRecruitingBasic ScienceTransient ischemia attacks1
Not AvailableRecruitingDiagnosticPostoperative Cognitive Dysfunction1
Not AvailableRecruitingDiagnosticTransesophageal Echocardiography Contrast Agents1
Not AvailableRecruitingDiagnosticVentricular Tachycardia (VT)1
Not AvailableRecruitingOtherMitochondrial Diseases1
Not AvailableRecruitingPreventionAcute Kidney Injury (AKI) / Cognitive Disorders / Delirium1
Not AvailableRecruitingPreventionAcute Lung Injury (ALI)1
Not AvailableRecruitingPreventionAnaesthesia therapy1
Not AvailableRecruitingPreventionAnaesthesia therapy / Efficacy / ERCP / Safety1
Not AvailableRecruitingPreventionArterial Hypotension1
Not AvailableRecruitingPreventionCognitive Decline / Delirium / Post-operative Quality of Recovery1
Not AvailableRecruitingPreventionCognitive Impairment, Mild1
Not AvailableRecruitingPreventionCoughing / Elective Surgery1
Not AvailableRecruitingPreventionDelirium / Dexmedetomidine / Lower Extremity Problem / Propofol1
Not AvailableRecruitingPreventionHyperglycemia Stress1
Not AvailableRecruitingPreventionIntubation; Difficult or Failed1
Not AvailableRecruitingPreventionMyocardial Ischemia1
Not AvailableRecruitingPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableRecruitingSupportive CareAirway Remodelling1
Not AvailableRecruitingSupportive CareInguinal Hernias / Postoperative pain1
Not AvailableRecruitingSupportive CarePostoperative pain / Undescended Testis1
Not AvailableRecruitingSupportive CareRenal Transplant Recipient Patients1
Not AvailableRecruitingSupportive CareSpinal Anaesthesia1
Not AvailableRecruitingTreatmentAbscesses / Joint dislocations / Perianal Abscess1
Not AvailableRecruitingTreatmentAcute Respiratory Failure1
Not AvailableRecruitingTreatmentAnaesthesia therapy / Anesthesia Morbidity / Breast Neoplasm Female / Regional Anesthesia / Regional Anesthesia Morbidity1
Not AvailableRecruitingTreatmentAnaesthesia therapy / Arterial Hypotension1
Not AvailableRecruitingTreatmentAnaesthesia therapy / General Surgery / Pain1
Not AvailableRecruitingTreatmentAnoxic Encephalopathy / Cardiac Arrest / Refractory seizure disorders1
Not AvailableRecruitingTreatmentIntubated Requiring Sedation for Greater Than 48 Hours1
Not AvailableRecruitingTreatmentIschemia, Brain / Strokes1
Not AvailableRecruitingTreatmentMajor Depressive Disorder (MDD)1
Not AvailableRecruitingTreatmentMigrainous Headache1
Not AvailableRecruitingTreatmentMyocardial Infarction (MI)1
Not AvailableRecruitingTreatmentNonvalvular Atrial Fibrillation1
Not AvailableRecruitingTreatmentPeripheral Solitary Pulmonary Nodule or Tuberculoma1
Not AvailableRecruitingTreatmentRupture of Anterior Cruciate Ligament / Tear of Anterior Cruciate Ligament1
Not AvailableRecruitingTreatmentStatus;Splenectomy1
Not AvailableRecruitingTreatmentThe Comparison of the I-gel and Endotracheal Tube About in Different Ventilation Settings During Laparoscopic Surgery1
Not AvailableSuspendedSupportive CareNeoplasms, Malignant1
Not AvailableSuspendedTreatmentPaediatric Flexible Bronchoscopy1
Not AvailableTerminatedNot AvailableAbdominal Aortic Aneurysms (AAA) / Open Thoracoabdominal Aneurysm Repair / Thoracoabdominal Aneursym Repair With Cardiopulmonary Bypass / Thoracoabdominal Aneursym Stent / Thoracoabdominal Aneurysm Repair With Cardiopulmonary Bypass / Thoracoabdominal Aneurysm Stent1
Not AvailableTerminatedNot AvailableAnaesthesia therapy1
Not AvailableTerminatedNot AvailableBenign/Malignant Neoplasm / Gynecology for Benign/Malignant Neoplasm / Long Bone Fracture1
Not AvailableTerminatedDiagnosticParkinson's Disease (PD)1
Not AvailableTerminatedPreventionPostoperative pain / Varicosities of the great saphenous vein1
Not AvailableTerminatedTreatmentAnaesthesia therapy / Surgery, Cardiac1
Not AvailableTerminatedTreatmentBMI >30 kg/m2 / Sleep Apnea, Obstructive1
Not AvailableTerminatedTreatmentChronic Rhinosinusitis1
Not AvailableTerminatedTreatmentLiver Diseases1
Not AvailableTerminatedTreatmentMigrainous Headache1
Not AvailableTerminatedTreatmentPain1
Not AvailableTerminatedTreatmentProcedural Sedation / Procedural Sedation and Analgesia1
Not AvailableTerminatedTreatmentAdjunct to general anesthesia therapy1
Not AvailableUnknown StatusNot AvailableAneurism / Intestinal Fistula / Intestinal Obstruction / Liver Cirrhosis / Neoplasms, Abdominal1
Not AvailableUnknown StatusNot AvailableChildren Requiring Sedation for MRI/CT1
Not AvailableUnknown StatusNot AvailableLung Cancers / Neoplasms, Lung1
Not AvailableUnknown StatusNot AvailableOxidative Stress1
Not AvailableUnknown StatusNot AvailableFunctional disorders of the biliary tract / Pancreatic Diseases1
Not AvailableUnknown StatusNot AvailableTarget Controlled Infusion of Propofol1
Not AvailableUnknown StatusBasic ScienceAnaesthesia therapy1
Not AvailableUnknown StatusBasic SciencePhobic Disorders1
Not AvailableUnknown StatusPreventionStrabismus1
Not AvailableUnknown StatusScreeningAnesthesia Recovery Period / Delirium, Dementia, Cognitive Disorders / Mental Competency / Neurobehavioural Manifestation1
Not AvailableUnknown StatusSupportive CareDiverticulosis, Colonic / Malignant Neoplasm of Colon / Rectal Carcinoma1
Not AvailableUnknown StatusSupportive CareAdjunct to general anesthesia therapy1
Not AvailableUnknown StatusTreatmentBMI >30 kg/m2 / Pharmacodynamics1
Not AvailableUnknown StatusTreatmentChronic Lung Diseases1
Not AvailableUnknown StatusTreatmentHemolysis1
Not AvailableUnknown StatusTreatmentLiver Diseases1
Not AvailableUnknown StatusTreatmentArterial hypoxia1
Not AvailableWithdrawnNot AvailableOptic Nerve Sheath1
Not AvailableWithdrawnPreventionNeoplasms, Brain1
Not AvailableWithdrawnPreventionRespiratory Complications / Swallowing Disorders1
Pharmacoeconomics
Manufacturers
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Teva parenteral medicines inc
Packagers
Dosage forms
FormRouteStrength
EmulsionIntravenous1 %
Injection, emulsionIntravenous10 mg/mL
EmulsionIntravenous10 mg
Prices
Unit descriptionCostUnit
Diprivan 10 mg/ml vial0.93USD ml
Propoven 1000 mg/100 ml vial0.19USD ml
Propoven 200 mg/20 ml ampul0.19USD ml
Propoven 500 mg/50 ml vial0.19USD ml
Propofol 10 mg/ml vial0.13USD ml
Propofol 1% emulsion vial0.1USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2212794 No2000-09-122015-03-17Canada
US8476010 Yes2005-06-012025-06-01Us
US5908869 Yes1995-09-222015-09-22Us
US5731356 Yes1995-09-222015-09-22Us
US5731355 Yes1995-09-222015-09-22Us
US5714520 Yes1995-09-222015-09-22Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point (°C)18 °CPhysProp
boiling point (°C)256 °CPhysProp
water solubility124 mg/LNot Available
logP3.79HANSCH,C ET AL. (1995)
pKa11.1 (at 20 °C)SERJEANT,EP & DEMPSEY,B (1979)
Predicted Properties
PropertyValueSource
Water Solubility0.158 mg/mLALOGPS
logP3.81ALOGPS
logP4.16ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)10.98ChemAxon
pKa (Strongest Basic)-5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area20.23 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity56.42 m3·mol-1ChemAxon
Polarizability21.61 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9955
Blood Brain Barrier+0.9381
Caco-2 permeable+0.9153
P-glycoprotein substrateNon-substrate0.722
P-glycoprotein inhibitor INon-inhibitor0.9343
P-glycoprotein inhibitor IINon-inhibitor0.9883
Renal organic cation transporterNon-inhibitor0.9036
CYP450 2C9 substrateNon-substrate0.7352
CYP450 2D6 substrateSubstrate0.7838
CYP450 3A4 substrateNon-substrate0.5667
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9368
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9196
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7429
Ames testNon AMES toxic0.9282
CarcinogenicityNon-carcinogens0.7195
BiodegradationNot ready biodegradable0.7808
Rat acute toxicity2.2996 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8987
hERG inhibition (predictor II)Non-inhibitor0.9087
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Download (7.9 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-03di-2900000000-52d81dde2dccf378a450View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cumenes. These are aromatic compounds containing a prop-2-ylbenzene moiety.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassCumenes
Direct ParentCumenes
Alternative ParentsPhenylpropanes / 1-hydroxy-4-unsubstituted benzenoids / Organooxygen compounds / Hydrocarbon derivatives
SubstituentsPhenylpropane / Cumene / 1-hydroxy-4-unsubstituted benzenoid / Phenol / Organic oxygen compound / Hydrocarbon derivative / Organooxygen compound / Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptorsphenols (CHEBI:44915 ) / a small molecule (CPD-11437 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB2
Uniprot ID:
P47870
Uniprot Name:
Gamma-aminobutyric acid receptor subunit beta-2
Molecular Weight:
59149.895 Da
References
  1. Franks NP: Molecular targets underlying general anaesthesia. Br J Pharmacol. 2006 Jan;147 Suppl 1:S72-81. [PubMed:16402123 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-gated chloride ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB3
Uniprot ID:
P28472
Uniprot Name:
Gamma-aminobutyric acid receptor subunit beta-3
Molecular Weight:
54115.04 Da
References
  1. Franks NP: Molecular targets underlying general anaesthesia. Br J Pharmacol. 2006 Jan;147 Suppl 1:S72-81. [PubMed:16402123 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. This sodium channel may be present in both denervated and innervated skeleta...
Gene Name:
SCN4A
Uniprot ID:
P35499
Uniprot Name:
Sodium channel protein type 4 subunit alpha
Molecular Weight:
208059.175 Da
References
  1. Haeseler G, Karst M, Foadi N, Gudehus S, Roeder A, Hecker H, Dengler R, Leuwer M: High-affinity blockade of voltage-operated skeletal muscle and neuronal sodium channels by halogenated propofol analogues. Br J Pharmacol. 2008 Sep;155(2):265-75. doi: 10.1038/bjp.2008.255. Epub 2008 Jun 23. [PubMed:18574460 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient.
Gene Name:
SCN2A
Uniprot ID:
Q99250
Uniprot Name:
Sodium channel protein type 2 subunit alpha
Molecular Weight:
227972.64 Da
References
  1. Haeseler G, Karst M, Foadi N, Gudehus S, Roeder A, Hecker H, Dengler R, Leuwer M: High-affinity blockade of voltage-operated skeletal muscle and neuronal sodium channels by halogenated propofol analogues. Br J Pharmacol. 2008 Sep;155(2):265-75. doi: 10.1038/bjp.2008.255. Epub 2008 Jun 23. [PubMed:18574460 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Uniprot Name:
Cytochrome P450 2C9
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Uniprot Name:
Cytochrome P450 2B6
Molecular Weight:
56277.81 Da
References
  1. Walsky RL, Astuccio AV, Obach RS: Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol. 2006 Dec;46(12):1426-38. [PubMed:17101742 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A8
Uniprot ID:
Q9HAW9
Uniprot Name:
UDP-glucuronosyltransferase 1-8
Molecular Weight:
59741.035 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Uniprot Name:
UDP-glucuronosyltransferase 1-9
Molecular Weight:
59940.495 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Takahashi H, Maruo Y, Mori A, Iwai M, Sato H, Takeuchi Y: Effect of D256N and Y483D on propofol glucuronidation by human uridine 5'-diphosphate glucuronosyltransferase (UGT1A9). Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):131-6. doi: 10.1111/j.1742-7843.2008.00247.x. [PubMed:18816295 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Uniprot Name:
UDP-glucuronosyltransferase 1-1
Molecular Weight:
59590.91 Da
References
  1. Mano Y, Usui T, Kamimura H: Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4. [PubMed:17697043 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Fatty acid amide hydrolase activity
Specific Function:
Degrades bioactive fatty acid amides like oleamide, the endogenous cannabinoid, anandamide and myristic amide to their corresponding acids, thereby serving to terminate the signaling functions of these molecules. Hydrolyzes polyunsaturated substrate anandamide preferentially as compared to monounsaturated substrates.
Gene Name:
FAAH
Uniprot ID:
O00519
Uniprot Name:
Fatty-acid amide hydrolase 1
Molecular Weight:
63065.28 Da
References
  1. Zhu F, Han B, Kumar P, Liu X, Ma X, Wei X, Huang L, Guo Y, Han L, Zheng C, Chen Y: Update of TTD: Therapeutic Target Database. Nucleic Acids Res. 2010 Jan;38(Database issue):D787-91. doi: 10.1093/nar/gkp1014. Epub 2009 Nov 20. [PubMed:19933260 ]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Uniprot Name:
Cytochrome P450 2E1
Molecular Weight:
56848.42 Da
References
  1. Chen TL, Ueng TH, Chen SH, Lee PH, Fan SZ, Liu CC: Human cytochrome P450 mono-oxygenase system is suppressed by propofol. Br J Anaesth. 1995 May;74(5):558-62. [PubMed:7772432 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Uniprot Name:
Cytochrome P450 1B1
Molecular Weight:
60845.33 Da
References
  1. Chen TL, Ueng TH, Chen SH, Lee PH, Fan SZ, Liu CC: Human cytochrome P450 mono-oxygenase system is suppressed by propofol. Br J Anaesth. 1995 May;74(5):558-62. [PubMed:7772432 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Uniprot Name:
Cytochrome P450 1A1
Molecular Weight:
58164.815 Da
References
  1. Chen TL, Ueng TH, Chen SH, Lee PH, Fan SZ, Liu CC: Human cytochrome P450 mono-oxygenase system is suppressed by propofol. Br J Anaesth. 1995 May;74(5):558-62. [PubMed:7772432 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Uniprot Name:
Cytochrome P450 1A2
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Uniprot Name:
Cytochrome P450 2A6
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Uniprot Name:
Cytochrome P450 2C18
Molecular Weight:
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Uniprot Name:
Cytochrome P450 2C19
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Uniprot Name:
Cytochrome P450 2C8
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Uniprot Name:
Cytochrome P450 2D6
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Uniprot Name:
Cytochrome P450 3A4
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein homodimerization activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 3 lacks transferase activity but acts as a negative regulator of isoform 1 (By similarity).
Gene Name:
UGT1A6
Uniprot ID:
P19224
Uniprot Name:
UDP-glucuronosyltransferase 1-6
Molecular Weight:
60750.215 Da
References
  1. Gu J, Lu K, Xia P, Tang M, Dai Q, Ma D, Tao G: Pharmacokinetics of propofol and extrahepatic UGT1A6 gene expression in anhepatic rats. Pharmacology. 2009;84(4):219-26. doi: 10.1159/000236523. Epub 2009 Sep 10. [PubMed:19752585 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Uniprot Name:
Serum albumin
Molecular Weight:
69365.94 Da
References
  1. Bright DP, Adham SD, Lemaire LC, Benavides R, Gruss M, Taylor GW, Smith EH, Franks NP: Identification of anesthetic binding sites on human serum albumin using a novel etomidate photolabel. J Biol Chem. 2007 Apr 20;282(16):12038-47. Epub 2007 Feb 20. [PubMed:17311911 ]
  2. Liu R, Eckenhoff RG: Weak polar interactions confer albumin binding site selectivity for haloether anesthetics. Anesthesiology. 2005 Apr;102(4):799-805. [PubMed:15791110 ]
  3. Sawas AH, Pentyala SN, Rebecchi MJ: Binding of volatile anesthetics to serum albumin: measurements of enthalpy and solvent contributions. Biochemistry. 2004 Oct 5;43(39):12675-85. [PubMed:15449957 ]
  4. Schywalsky M, Ihmsen H, Knoll R, Schwilden H: Binding of propofol to human serum albumin. Arzneimittelforschung. 2005;55(6):303-6. [PubMed:16032968 ]
Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 10:32